Home » Elscint Holding Gamida-Cell, Teva to Develop and Commercialize StemEx
Elscint Holding Gamida-Cell, Teva to Develop and Commercialize StemEx
Elscint Ltd. announced that Teva Pharmaceutical Industries
Ltd. has exercised its option to enter into a joint venture with Gamida-Cell
Ltd., in which Elscint (through a wholly owned subsidiary) holds 29.2 percent
on a fully diluted basis, in order to develop and commercialize StemEx for the
treatment of Leukemia and Lymphoma.
Yahoo
News
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
07May
-
14May
-
30May